In-Pharmatechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals.
Dr. Arie Belldegrun has been appointed to the board of Teva Pharmaceuticals until the next shareholders meeting in order to fill a vacancy.
Dr. Belldegrun - who currently serves as Chairman of the Board at Kite, Arno Therapeutics and Theracoat - is a director of the UCLA Institute of Urologic Oncology and Professor and Chair of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles.
Teva’s Chairman, Dr. Phillip Frost, welcomed Dr. Belldegrun and said his “extensive experience in the pharmaceutical industry both as a doctor, a business leader and an academic will enable him to make significant contributions to the Board immediately.”
Mats Pettersson (left) has announced that he will not be seeking re-election on the Board of Directors at H. Lundbeck after the company’s annual general meeting on 21 March.
Pettersson leaves the company after 10 years and his position of Chairman will go to Håkan Björklund (centre) if he is re-elected at the upcoming meeting.
Petersson said: "Lundbeck is well prepared to face the future, building on its strong platform for long-term growth, and I have decided that this was the right time to pass the baton to a new board member and chairman."
The Board has nominated President and CEO of Coloplast A/S, Lars Rasmussen (right), as a new member.
Speciality Pharmaceutical Company AcelRx has announced the appointment of Adrian Adams as its new Chairman of the Board of Directors.
Adams, currently the CEO and President of Auxilium Pharmaceuticals, has over 30 years of experience in the pharmaceutical industry including roles at Inspire, Kos, ICI, SmithKline Beecham and Novartis.
He replaces Thomas Schreck, co-founder of AcelRx, about whom President and CEO Richard King said: "We have made great headway over the past two years, and I thank Tom for his entrepreneurial vision, years of devoted leadership and commitment to AcelRx as we move to this next stage."
Life Science firm OvaScience has appointed Dr. Harald Stock to its Board of Directors.
Stock, who previously has worked in high-end roles at divisions in Roche and Johnson & Johnson, has served as CEO of the Grünenthal Group, an international research-based pharmaceutical company headquartered in Germany, since 2009.
“The global fertility market is nearly 10 times larger than the U.S. alone, and growing rapidly,” said Dr. Michell Dipp, CEO of OvaScience, adding that “Harald’s expertise and success commercializing products in global healthcare markets will be important to OvaScience as we advance our ex-U.S. strategy.”
Dr. William “Wes” F. Westlin has been appointed Head of Preclinical Research and Early Development at biotech company Nimbus Discovery.
Westlin has over 20 years experience in the field of drug discovery and comes from Avila where he was responsible for all of the company’s preclinical efforts.
Dr. Rosana Kapeller Chief Scientific Officer of Nimbus said: “Wes is an outstanding scientific leader who will help us accelerate our IRAK4 and ACC programs towards early proof of concept in the clinic.”
As Precision Biopsy announces successful Phase 1 clinical trials of its prostate cancer diagnosis technology, it also announces the appointment of Amir Tehrani as its new CEO.
Prior to the role, Tehrani served as CEO at Amaranth Medical.
“With over 20 years of experience in strategy, marketing, design and development for both Fortune 500 and start-up medical device companies, I am confident in Amir’s ability to lead Precision Biopsy to commercial success,” said Dr. Omar Amirana, Managing Director at Allied Minds, Precision’s parent body.
Jonathan E. Dickinson has been appointed as European General Manager at Ariad Pharmaceuticals in a number of key leadership changes.
Prior to Ariad, Dickinson served three years at Bristol-Myers Squibb and has also spent 13 years in key leadership roles at Hoffmann-La Roche.
Dr. Harvey J. Berger, chairman and chief executive officer of ARIAD said: “Jonathan is a proven leader with broad commercial and general management experience promoting several of the most highly regarded oncology medicines available today.”
Other key appointments at Ariad include:
- Anna Casse – Head, Marketing and Sales
- Anant Murthy, Ph.D. – Head, Pricing, Reimbursement and Access
- Kai C. Chan, M.D. - Head, Medical Affairs
- Thierry Bataillard – Head, Regulatory Affairs